Akouos, Inc. (AKUS)

Market Cap	250.92M
Revenue (ttm)	n/a
Net Income (ttm)	-95.66M
Shares Out	36.90M
EPS (ttm)	-2.83
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	156,044
Open	6.75
Previous Close	6.76
Day's Range	6.63 - 7.08
52-Week Range	2.32 - 11.43
Beta	-0.10
Analysts	Buy
Price Target	20.91 (+207.5%)
Earnings Date	Nov 10, 2022

About AKUS

Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibul...

• Industry: Biotechnology
• IPO Date: Jun 26, 2020
• Employees: 103
• Stock Exchange: NASDAQ
• Ticker Symbol: AKUS

Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for AKUS stock is "Buy." The 12-month stock price forecast is 20.91, which is an increase of 207.50% from the latest price.

Price Target

$20.91

(207.50% upside)

Analyst Consensus: Buy

Stock Forecasts